Mallinckrodt in its reorganization process, Chapter 11 bankruptcy emergence, issuance of $650 million in aggregate principal amount of new first lien senior secured notes and completion of Irish Examinership proceedings

On June 16, 2022, Mallinckrodt plc announced that it has successfully completed its reorganization process, emerged from Chapter 11 and completed the Irish Examinership proceedings.  Mallinckrodt is moving forward as a diversified global specialty pharmaceutical company with a strengthened balance sheet and increased financial flexibility to invest in its business, execute its strategic initiatives, advance its pipeline and better meet the needs of patients. In connection with emergence, Mallinckrodt issued $650 million in aggregate principal amount of new first lien senior secured notes. Wachtell, Lipton, Rosen & Katz served as legal advisor to Mallinckrodt.